Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial -

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial
Information type: Other primary research
Source: The Lancet
Specialities: Cardiovascular system disorders | Diabetes | Surgery
Summary
Sub-group analysis (n=11,154) reported that addition of ticagrelor to aspirin reduced cardiovascular death, MI, and stroke vs placebo for a median of 3.3 years (7.3 vs 8.6% in the PCI group; HR 0.85; 95% CI 0.74–0.97; p=0.013), although with increased risk of major bleeding.
UKMi comment
A related commentary notes that the combination of ticagrelor and aspirin may potentially represent a new treatment option for patients with stable coronary artery disease and diabetes undergoing PCI. However, the results are based on a large sub-group analysis and optimal patient selection, timing of treatment initiation, and treatment duration remain unclear.
Related links: Commentary